- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT06561360
En studie av Vemurafenib og Obinutuzumab sammenlignet med Cladribine og Rituximab hos personer med hårcelleleukemi (HCL)
En randomisert, multisenter, fase II-studie av Vemurafenib Plus Obinutuzumab vs. Cladribine Plus Rituximab hos pasienter med tidligere ubehandlet hårcelleleukemi (HCL)
The researchers are doing this study to compare the safety of vemurafenib in combination with obinutuzumab to the standard of approach of cladribine in combination with rituximab. The researchers will look at which treatment causes fewer or milder side effects. Researchers think vemurafenib and obinutuzumab (non-chemotherapy drugs) may cause fewer side effects compared with the usual approach of chemotherapy drugs. They will also compare the two approaches to see which approach is more effective at eliminating cancer cells.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Studietype
Registrering (Antatt)
Fase
- Fase 2
Kontakter og plasseringer
Studiekontakt
- Navn: Jae Park, MD
- Telefonnummer: 646-608-3743
- E-post: parkj6@mskcc.org
Studer Kontakt Backup
- Navn: Mark Geyer, MD
- Telefonnummer: 646-608-3745
Studiesteder
-
-
Massachusetts
-
Boston, Massachusetts, Forente stater, 02115
- Har ikke rekruttert ennå
- Dana Farber Cancer Institute
-
Ta kontakt med:
- Eric Winer, MD
- Telefonnummer: (617) 632-6876
-
-
Minnesota
-
Rochester, Minnesota, Forente stater, 55905
- Har ikke rekruttert ennå
- Mayo Clinic Cancer Center
-
Ta kontakt med:
- Sameer Parikh, M.B.B.S.
- Telefonnummer: 507-218-0772
-
-
New Jersey
-
Basking Ridge, New Jersey, Forente stater, 07920
- Rekruttering
- Memorial Sloan Kettering at Basking Ridge (All Protocol Activities)
-
Ta kontakt med:
- Jae Park, MD
- Telefonnummer: 646-608-3743
-
Middletown, New Jersey, Forente stater, 07748
- Rekruttering
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities)
-
Ta kontakt med:
- Jae Park, MD
- Telefonnummer: 646-608-3743
-
Montvale, New Jersey, Forente stater, 07645
- Rekruttering
- Memorial Sloan Kettering Bergen (Limited Protocol Activities)
-
Ta kontakt med:
- Jae Park, MD
- Telefonnummer: 646-608-3743
-
-
New York
-
Commack, New York, Forente stater, 11725
- Rekruttering
- Memorial Sloan Kettering Cancer Commack - Suffolk (Limited Protocol Activities)
-
Ta kontakt med:
- Jae Park, MD
- Telefonnummer: 646-608-3743
-
Harrison, New York, Forente stater, 10604
- Rekruttering
- Memorial Sloan Kettering Westchester (All Protocol Activities)
-
Ta kontakt med:
- Jae Park, MD
- Telefonnummer: 646-608-3743
-
New York, New York, Forente stater, 10065
- Rekruttering
- Memorial Sloan Kettering Cancer Center (All Protocol Activities)
-
Ta kontakt med:
- Jae Park, MD
- Telefonnummer: 646-608-3743
-
Uniondale, New York, Forente stater, 11553
- Rekruttering
- Memorial Sloan Kettering Nassau (Limited Protocol Activities)
-
Ta kontakt med:
- Jae Park, MD
- Telefonnummer: 646-608-3743
-
-
Ohio
-
Columbus, Ohio, Forente stater, 43210
- Rekruttering
- Ohio State University
-
Ta kontakt med:
- Seema Bhat, MD
- Telefonnummer: 614-293-3196
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
-
Patients must be ≥ 18 years of age
-
Histologically confirmed classical HCL by the enrolling institution
-
Presence of BRAF V600E mutation as confirmed by PCR, NGS or immunohistochemistry. If patient is known to have negative BRAF mutation, repeat testing is advisable as well as discussion with the main study principal investigator.
-
Has not received any prior therapy for the disease
-
Patients who meet the standard treatment initiation criteria, as defined by ANC ≤1.0, Hgb ≤ 10.0 or PLT ≤100K
-
ECOG performance status of 0 - 2
-
Acceptable pre-study organ function during screening as defined as:
- Total bilirubin ≤ 1.5 times the upper limit of normal (ULN), except in patients with known Gilbert's syndrome who may be enrolled if direct bilirubin ≤ 3 x ULN);
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5x ULN; and
- Serum creatinine ≤ 1.5x ULN
-
Electrocardiogram (ECG) without evidence of clinically significant ventricular arrhythmias or ischemia as determined by the investigator and a rate-corrected QT interval (QTc, Bazett's formula) of < 480 msec
-
For women of childbearing potential, agreement to the use of two acceptable methods of contraception, including one barrier method, during the study and for 6 months after discontinuation of vemurafenib and cladribine, and 18 months after discontinuation of rituximab and obinutuzumab
-
For men with female partners of childbearing potential, agreement to use a latex condom and to advise their female partner to use an additional method of contraception during the study and for 6 months after discontinuation of vemurafenib
-
Negative serum pregnancy test within 7 days of commencement of treatment in women of childbearing potential
Exclusion Criteria:
-
Have had previous treatment for HCL, including purine analogs, vemurafenib, rituximab, obinutuzumab, and other investigational agents. Previous treatment with transfusions and other supportive care such as G-CSF and erythropoietin are allowed.
-
Known hypersensitivity to any of the study drugs.
-
Patients with known long QT syndrome or uncorrectable electrolyte abnormalities
-
Clinically significant history of liver disease, including viral or other hepatitis, current alcohol abuse, or cirrhosis.
-
Presence of positive test results for hepatitis B virus (HBV), hepatitis B surface antigen (HBsAg) or hepatitis C (HCV) antibody
° Patients with occult or prior HBV infection (defined as positive total hepatitis B core antibody [HBcAb] and negative HBsAg) may be included if HBV DNA is undetectable. These patients must be willing to undergo monthly DNA testing and take HBV viral prophylaxis such as entecavir.
-
Known infection with HIV or human T-cell leukemia virus 1 (HTLV-1)
-
Active uncontrolled infection, e.g. persistent bacteremia, supplemental oxygen or pressor supports, etc.
-
Live vaccination within 28 days of randomization
-
Patients with concurrent active malignancies as defined by malignancies requiring any therapy other than expectant observation or hormonal therapy, with the exception of squamous and basal cell carcinoma of the skin, in situ cervical cancer, adequately treated stage I/II cancer from which the patient is current in complete remission, or any other cancer from which the patient has been disease free for five years
-
Malabsorption syndrome or other condition that precludes enteral route of administration
-
Patients with HCL variant (as defined by absence of expression of CD25)
-
Pregnant or lactating, or intending to become pregnant during the study
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Vemurafenib plus Obinutuzumab
Patients assigned to the study arm will receive vemurafenib orally twice daily (b.i.d.) continuously in cycles of 4 weeks (28 days) for a total of 4 cycles. Obinutuzumab will be administered concomitantly with vemurafenib starting at cycle 2 of treatment in cycles of 4 weeks. Obinutuzumab infusions will be administered on days 1, 8 and 15 during the cycle 2 and every 4 weeks during the cycle 3 and 4 of treatment. |
Vemurafenib orally twice daily (b.i.d.) continuously in cycles of 4 weeks (28 days) for a total of 4 cycles. Obinutuzumab will be administered concomitantly with vemurafenib starting at cycle 2 of treatment in cycles of 4 weeks. |
|
Aktiv komparator: Standard treatment of Cladribine plus Rituximab
Patients assigned to the SOC arm will receive cladribine IV on days 1-5 concurrently with rituximab IV per week for 8 times, i.e., weekly x8 from day 1. |
Cladribine IV on days 1-5 concurrently with rituximab. Rituximab on days 1-5 concurrently with rituximab. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
incidences of ≥ grade 3 treatment-related toxicities
Tidsramme: within 6 months of treatment
|
per CTCAE v5.0 within first 6 months from the start of the treatment to account delayed toxicities of the treatments |
within 6 months of treatment
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
complete remission
Tidsramme: 2 years
|
Response will be determined by the Consensus Resolution response criteria. Complete response (CR)
|
2 years
|
|
partial response
Tidsramme: 2 years
|
Partial response (PR) °A normalization of cytopenias °≥50% reduction in organomegaly and bone marrow hairy cells. |
2 years
|
Samarbeidspartnere og etterforskere
Samarbeidspartnere
Etterforskere
- Hovedetterforsker: Jae Park, MD, Memorial Sloan Kettering Cancer Center
Publikasjoner og nyttige lenker
Hjelpsomme linker
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
- Neoplasmer
- Sykdommer i immunsystemet
- Neoplasmer etter histologisk type
- Hematologiske sykdommer
- Lymfesykdommer
- Lymfoproliferative lidelser
- Immunproliferative lidelser
- Leukemi
- Hemic og lymfatiske sykdommer
- Leukemi, hårcelle
- Aminosyrer, peptider og proteiner
- Proteiner
- Svovelforbindelser
- Organiske kjemikalier
- Heterocykliske forbindelser
- Heterocykliske forbindelser, 2-ring
- Heterocykliske forbindelser, smeltet ringen
- Nukleinsyrer, nukleotider og nukleosider
- Amides
- Indoler
- Antistoffer, monoklonalt
- Antistoffer
- Immunoglobuliner
- Immunoproteiner
- Blodproteiner
- Serumglobuliner
- Globuliner
- Puriner
- Nukleosider
- Ribonukleosider
- Antistoffer, monoklonale, murine-avledede
- Deoxyribonucleosides
- Sulfonamider
- Sulfoner
- 2-kloradenosin
- Adenosin
- Purin nukleosider
- Deoxyadenosines
- Rituximab
- Vemurafenib
- Kladribin
- Obinutuzumab
Andre studie-ID-numre
- 24-160
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .